Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.

Sun R, Skeiky YA, Izzo A, Dheenadhayalan V, Imam Z, Penn E, Stagliano K, Haddock S, Mueller S, Fulkerson J, Scanga C, Grover A, Derrick SC, Morris S, Hone DM, Horwitz MA, Kaufmann SH, Sadoff JC.

Vaccine. 2009 Jul 16;27(33):4412-23. doi: 10.1016/j.vaccine.2009.05.048. Epub 2009 Jun 2.

PMID:
19500523
2.

Protective immune responses to a recombinant adenovirus type 35 tuberculosis vaccine in two mouse strains: CD4 and CD8 T-cell epitope mapping and role of gamma interferon.

Radosevic K, Wieland CW, Rodriguez A, Weverling GJ, Mintardjo R, Gillissen G, Vogels R, Skeiky YA, Hone DM, Sadoff JC, van der Poll T, Havenga M, Goudsmit J.

Infect Immun. 2007 Aug;75(8):4105-15. Epub 2007 May 25.

3.

Impact of MHC class I alleles on the M. tuberculosis antigen-specific CD8+ T-cell response in patients with pulmonary tuberculosis.

Weichold FF, Mueller S, Kortsik C, Hitzler WE, Wulf MJ, Hone DM, Sadoff JC, Maeurer MJ.

Genes Immun. 2007 Jun;8(4):334-43. Epub 2007 Apr 12.

PMID:
17429413
4.

Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope.

Wang X, Kochetkova I, Haddad A, Hoyt T, Hone DM, Pascual DW.

Vaccine. 2005 May 31;23(29):3836-42. Epub 2005 Mar 17.

PMID:
15893622
5.

M cell DNA vaccination for CTL immunity to HIV.

Wang X, Hone DM, Haddad A, Shata MT, Pascual DW.

J Immunol. 2003 Nov 1;171(9):4717-25.

6.

Progress toward the development of a bacterial vaccine vector that induces high-titer long-lived broadly neutralizing antibodies against HIV-1.

Fouts TR, DeVico AL, Onyabe DY, Shata MT, Bagley KC, Lewis GK, Hone DM.

FEMS Immunol Med Microbiol. 2003 Jul 15;37(2-3):129-34. Review.

7.
8.

Development of vaccination strategies that elicit broadly neutralizing antibodies against human immunodeficiency virus type 1 in both the mucosal and systemic immune compartments.

Hone DM, DeVico AL, Fouts TR, Onyabe DY, Agwale SM, Wambebe CO, Blattner WA, Gallo RC, Lewis GK.

J Hum Virol. 2002 Jan-Feb;5(1):17-23. Review.

PMID:
12352264
9.

A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice.

Agwale SM, Shata MT, Reitz MS Jr, Kalyanaraman VS, Gallo RC, Popovic M, Hone DM.

Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10037-41. Epub 2002 Jul 2.

10.

Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1.

Devico AL, Fouts TR, Shata MT, Kamin-Lewis R, Lewis GK, Hone DM.

Vaccine. 2002 May 6;20(15):1968-74. Review.

PMID:
11983256
11.

Mucosal and systemic HIV-1 Env-specific CD8(+) T-cells develop after intragastric vaccination with a Salmonella Env DNA vaccine vector.

Shata MT, Reitz MS Jr, DeVico AL, Lewis GK, Hone DM.

Vaccine. 2001 Nov 12;20(3-4):623-9.

PMID:
11672930
13.

Recent advances with recombinant bacterial vaccine vectors.

Shata MT, Stevceva L, Agwale S, Lewis GK, Hone DM.

Mol Med Today. 2000 Feb;6(2):66-71. Review.

PMID:
10652479
14.

Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response.

Pascual DW, Hone DM, Hall S, van Ginkel FW, Yamamoto M, Walters N, Fujihashi K, Powell RJ, Wu S, Vancott JL, Kiyono H, McGhee JR.

Infect Immun. 1999 Dec;67(12):6249-56.

15.
16.

Regulation of host immune responses by modification of Salmonella virulence genes.

VanCott JL, Chatfield SN, Roberts M, Hone DM, Hohmann EL, Pascual DW, Yamamoto M, Kiyono H, McGhee JR.

Nat Med. 1998 Nov;4(11):1247-52.

PMID:
9809547
20.

Release of tumor necrosis factor alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models.

Powell JL, Wright AC, Wasserman SS, Hone DM, Morris JG Jr.

Infect Immun. 1997 Sep;65(9):3713-8.

21.

Oral bacterial vaccine vectors for the delivery of subunit and nucleic acid vaccines to the organized lymphoid tissue of the intestine.

Pascual DW, Powell RJ, Lewis GK, Hone DM.

Behring Inst Mitt. 1997 Feb;(98):143-52. Review.

PMID:
9382735
22.

Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses.

Hone DM, Wu S, Powell RJ, Pascual DW, Van Cott J, McGhee J, Fouts TR, Tuskan RG, Lewis GK.

J Biotechnol. 1996 Jan 26;44(1-3):203-7. Review.

PMID:
8717405
23.

Construction and immunogenicity of Salmonella typhimurium vaccine vectors that express HIV-1 gp120.

Fouts TR, Tuskan RG, Chada S, Hone DM, Lewis GK.

Vaccine. 1995 Dec;13(17):1697-705.

PMID:
8719522
25.
26.

Construction and characterization of attenuated delta aroA delta virG Shigella flexneri 2a strain CVD 1203, a prototype live oral vaccine.

Noriega FR, Wang JY, Losonsky G, Maneval DR, Hone DM, Levine MM.

Infect Immun. 1994 Nov;62(11):5168-72.

27.
28.

Construction and characterization of isogenic O-antigen variants of Salmonella typhi.

Hone DM, Harris AM, Lim V, Levine MM.

Mol Microbiol. 1994 Aug;13(3):525-30.

PMID:
7527893
29.

Expression of human immunodeficiency virus antigens in an attenuated Salmonella typhi vector vaccine.

Hone DM, Lewis GK, Beier M, Harris A, McDaniels T, Fouts TR.

Dev Biol Stand. 1994;82:159-62. Review.

PMID:
7958470
30.

Evaluation in volunteers of a candidate live oral attenuated Salmonella typhi vector vaccine.

Hone DM, Tacket CO, Harris AM, Kay B, Losonsky G, Levine MM.

J Clin Invest. 1992 Aug;90(2):412-20.

31.

Further consideration of the clonal nature of Salmonella typhi: evaluation of molecular and clinical characteristics of strains from Indonesia and Peru.

Franco A, Gonzalez C, Levine OS, Lagos R, Hall RH, Hoffman SL, Moechtar MA, Gotuzzo E, Levine MM, Hone DM, et al.

J Clin Microbiol. 1992 Aug;30(8):2187-90.

32.

Comparison of the safety and immunogenicity of delta aroC delta aroD and delta cya delta crp Salmonella typhi strains in adult volunteers.

Tacket CO, Hone DM, Curtiss R 3rd, Kelly SM, Losonsky G, Guers L, Harris AM, Edelman R, Levine MM.

Infect Immun. 1992 Feb;60(2):536-41.

33.

Clinical acceptability and immunogenicity of CVD 908 Salmonella typhi vaccine strain.

Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, Levine MM.

Vaccine. 1992;10(7):443-6.

PMID:
1609547
34.

Construction of genetically defined double aro mutants of Salmonella typhi.

Hone DM, Harris AM, Chatfield S, Dougan G, Levine MM.

Vaccine. 1991 Nov;9(11):810-6.

PMID:
1759503
35.

A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans.

Hone DM, Attridge SR, Forrest B, Morona R, Daniels D, LaBrooy JT, Bartholomeusz RC, Shearman DJ, Hackett J.

Infect Immun. 1988 May;56(5):1326-33.

Supplemental Content

Support Center